Trifluridine/tipiracil with or without bevacizumab in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: A retrospective observational study
Authors:
Open Access
- 6 August 2026
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Abstract
Background: Patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) have been reported to exhibit resistance to various cytotoxic agents, including fluorouracil. A preclinical study showed that trifluridine, a key active component of FTD/TPI, retained antitumor activity in 5-FU-refractory dMMR CRC cell lines. However, the efficacy of trifluridine/tipiracil (FTD/TPI), with or without bevacizumab, in patients with MSI-H/dMMR mCRC remains poorly understood. Objectives: This study aimed to evaluate the clinical efficacy and safety of FTD/TPI, with or without bevacizumab, specifically in patients with MSI-H/dMMR mCRC. Design: A retrospective, multicenter observational study was conducted across 10 hospitals in Japan. Methods: We identified patients with MSI-H/dMMR mCRC treated with FTD/TPI as second- or later-line therapy between June 2012 and January 2023. All eligible patients were divided into two groups: FTD/TPI monotherapy (FT group) and FTD/TPI combined with bevacizumab (FTB group); the safety and efficacy of the two groups were compared. Whole-exome sequencing (WES) was performed on available samples to explore genomic features associated with treatment response of FTD/TPI. Results: The objective response rate (ORR) was 16.7% (95% confidence interval [CI], 3.6–41.4); median progression-free survival (PFS) was 5.5 months, and median overall survival (OS) was 11.8 months in the overall cohort. Although the median PFS was similar between the two groups (5.6 months in the FTB group and 5.2 months in the FT group, p =0.34), the ORR (22.2% vs. 11.1%, p =0.53), disease control rate (DCR; 88.9% vs. 55.6%, p =0.77) and median OS (18.9 months in the FTB group and 7.1 months in the FT group, p =0.18) were numerically better in the FTB group. WES revealed diverse genomic alterations, including those affecting DNA double-strand break repair-related genes, but no clear genomic biomarkers predictive of treatment response were identified. Conclusions: FTD/TPI, with or without bevacizumab, demonstrated favorable antitumor activity in patients with MSI-H/dMMR mCRC. These findings suggest that FTD/TPI-based treatment may represent a potentially useful treatment option for this rare population, although further studies are warranted.Keywords
Funding Information
- Taiho Pharmaceutical Co., Ltd. Japan
This publication has 28 references indexed in Scilit:
- Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trialThe Lancet, 2025
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal CancerNew England Journal of Medicine, 2020
- TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 studyThe Lancet Oncology, 2017
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyThe Lancet Oncology, 2017
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in CancerThe Journal of Molecular Diagnostics, 2017
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2015
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The COSMIC (Catalogue of Somatic Mutations in Cancer) database and websiteBritish Journal of Cancer, 2004
- Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon CancerNew England Journal of Medicine, 2003